Yu S - Search Results

1

Exosomes: decreased sensitivity of lung cancer A549 cells to cisplatin.

Xiao X, Yu S, Li S, Wu J, Ma R, Cao H, Zhu Y, Feng J. Xiao X, et al. Among authors: yu s. PLoS One. 2014 Feb 21;9(2):e89534. doi: 10.1371/journal.pone.0089534. eCollection 2014. PLoS One. 2014. PMID: 24586853 Free PMC article.

2

Modified PNA-PCR method: a convenient and accurate method to screen plasma KRAS mutations of cancer patients.

Yu S, Wu J, Xu S, Tan G, Liu B, Feng J. Yu S, et al. Cancer Biol Ther. 2012 Mar;13(5):314-20. doi: 10.4161/cbt.19075. Epub 2012 Mar 1. Cancer Biol Ther. 2012. PMID: 22310974 Free article.

3

Colorectal cancer patients with low abundance of KRAS mutation may benefit from EGFR antibody therapy.

Yu S, Xiao X, Lu J, Qian X, Liu B, Feng J. Yu S, et al. PLoS One. 2013 Jul 9;8(7):e68022. doi: 10.1371/journal.pone.0068022. Print 2013. PLoS One. 2013. PMID: 23874486 Free PMC article.

4

Effect of EGFR-TKI retreatment following chemotherapy for advanced non-small cell lung cancer patients who underwent EGFR-TKI.

Xia GH, Zeng Y, Fang Y, Yu SR, Wang L, Shi MQ, Sun WL, Huang XE, Chen J, Feng JF. Xia GH, et al. Cancer Biol Med. 2014 Dec;11(4):270-6. doi: 10.7497/j.issn.2095-3941.2014.04.006. Cancer Biol Med. 2014. PMID: 25610713 Free PMC article.

5

Comparison of nedaplatin-based versus cisplatin-based chemotherapy for advanced non-small cell lung cancer among East Asian populations: A meta-analysis.

Liu Y, Yu S, Liu S, Cao H, Ma R, Wu J, Feng J. Liu Y, et al. Among authors: yu s. Sci Rep. 2015 May 21;5:10516. doi: 10.1038/srep10516. Sci Rep. 2015. PMID: 25994814 Free PMC article.

6

MicroRNA-339, an epigenetic modulating target is involved in human gastric carcinogenesis through targeting NOVA1.

Shen B, Zhang Y, Yu S, Yuan Y, Zhong Y, Lu J, Feng J. Shen B, et al. Among authors: yu s. FEBS Lett. 2015 Oct 7;589(20 Pt B):3205-11. doi: 10.1016/j.febslet.2015.09.009. Epub 2015 Sep 29. FEBS Lett. 2015. PMID: 26391641 Free article.

7

Tumor-derived exosomes in cancer progression and treatment failure.

Yu S, Cao H, Shen B, Feng J. Yu S, et al. Oncotarget. 2015 Nov 10;6(35):37151-68. doi: 10.18632/oncotarget.6022. Oncotarget. 2015. PMID: 26452221 Free PMC article. Review.

8

LXR ligands sensitize EGFR-TKI-resistant human lung cancer cells in vitro by inhibiting Akt activation.

Wu Y, Yu DD, Hu Y, Cao HX, Yu SR, Liu SW, Feng JF. Wu Y, et al. Biochem Biophys Res Commun. 2015 Nov 27;467(4):900-5. doi: 10.1016/j.bbrc.2015.10.047. Epub 2015 Oct 21. Biochem Biophys Res Commun. 2015. PMID: 26471306

9

WITHDRAWN: The long non-coding RNA, LINC00635-001, sensitizes EGFR-TKI-resistant human lung cancer cells in vitro by inhibiting Akt activation.

Wu Y, Yu DD, Hu Y, Yan DL, Chen X, Zhang HD, Cao HX, Yu SR, Wang Z, Feng JF. Wu Y, et al. Biochem Biophys Res Commun. 2016 Jan 11:S0006-291X(16)30057-2. doi: 10.1016/j.bbrc.2016.01.057. Online ahead of print. Biochem Biophys Res Commun. 2016. PMID: 26792719

10

Liver X receptor as a drug target for the treatment of breast cancer.

Wu Y, Yu DD, Yan DL, Hu Y, Chen D, Liu Y, Zhang HD, Yu SR, Cao HX, Feng JF. Wu Y, et al. Anticancer Drugs. 2016 Jun;27(5):373-82. doi: 10.1097/CAD.0000000000000348. Anticancer Drugs. 2016. PMID: 26872310 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

25,974 results

Search Page

Filters